Rapid and in-depth reconstruction of fluorine-doped bimetallic oxide in electrocatalytic oxygen evolution processes.

Most transition metal-based electrocatalysts, when used for the oxygen evolution reaction (OER), undergo significant restructuring under alkaline conditions, forming localized oxides/hydroxides (MOOH), which act as the real active centers, activating adjacent metal sites and creating new active sites that enhance electrocatalytic behavior. Nevertheless, inducing rapid and in-depth self-reconstruction of catalyst surfaces remains a huge challenge. Herein, this work achieves rapid and in-depth self-reconstruction by doping fluorine into the lattice of transition metal oxides (MO).

Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity.

Lipid nanoparticles (LNPs) for mRNA delivery have advanced significantly, but LNP-mediated DNA delivery still faces clinical challenges. This study compared various LNP formulations for delivering DNA-encoded biologics, assessing their expression efficacy and the protective immunity generated by LNP-encapsulated DNA in different models. The LNP formulation used in Moderna's Spikevax mRNA vaccine (LNP-M) demonstrated a stable nanoparticle structure, high expression efficiency, and low toxicity.

Sensor-combined organ-on-a-chip for pharmaceutical and medical sciences: from design and materials to typical biomedical applications.

Organ-on-a-chip (OoC) is a breakthrough technology in biomedicine. As microphysiological systems constructed , OoCs can simulate the main structures and functions of human organs, thereby providing a powerful tool for drug screening and disease model construction. Furthermore, the coupling of OoCs and sensors has been an innovative discovery in the field of biomedical and electronic engineering in recent years.

Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma.

Background: Siglec-E is an immune checkpoint inhibitory molecule. Expression of Siglec-E on the immune cells has been shown to promote tumor regression. This study aimed to develop an adenovirus (Ad) vaccine targeting Siglec-E and carbonic anhydrase IX (CAIX) (Ad-Siglec-E/CAIX) and to evaluate its potential antitumor effects in several preclinical renal cancer models.

Vaccines targeting p53 mutants elicit anti-tumor immunity.

The p53 tumor suppressor is commonly mutated in cancer; however, there are no effective treatments targeting p53 mutants. A DNA vaccine gWIZ-S237G targeting the p53 S237G mutant, which is highly expressed in A20 murine tumor cells, was developed and administered intramuscularly via electroporation, either alone or in combination with PD-1 blockade. The anti-p53-S237G immunization elicited a robust protective response against subcutaneous A20 tumors and facilitated the infiltration of immune cells including CD8 T cells, NK cells, and DCs.